Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.

Meike S, Yamamori T, Yasui H, Eitaki M, Matsuda A, Morimatsu M, Fukushima M, Yamasaki Y, Inanami O.

Mol Cancer. 2011 Jul 28;10:92. doi: 10.1186/1476-4598-10-92.

2.

A novel anticancer ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, enhances radiation-induced cell death in tumor cells.

Inanami O, Iizuka D, Iwahara A, Yamamori T, Kon Y, Asanuma T, Matsuda A, Kashiwakura I, Kitazato K, Kuwabara M.

Radiat Res. 2004 Dec;162(6):635-45.

PMID:
15548113
3.

X irradiation induces the proapoptotic state independent of the loss of clonogenic ability in Chinese hamster V79 cells.

Iizuka D, Inanami O, Matsuda A, Kashiwakura I, Asanuma T, Kuwabara M.

Radiat Res. 2005 Jul;164(1):36-44.

PMID:
15966763
4.

Treatment combining X-irradiation and a ribonucleoside anticancer drug, TAS106, effectively suppresses the growth of tumor cells transplanted in mice.

Yasui H, Inanami O, Asanuma T, Iizuka D, Nakajima T, Kon Y, Matsuda A, Kuwabara M.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):218-28.

PMID:
17448876
5.

Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells.

Du LQ, Du XQ, Bai JQ, Wang Y, Yang QS, Wang XC, Zhao P, Wang H, Liu Q, Fan FY.

J Cancer Res Clin Oncol. 2012 May;138(5):811-8. doi: 10.1007/s00432-011-1132-8. Epub 2012 Jan 25.

PMID:
22274865
6.

Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo.

Yasui H, Ogura A, Asanuma T, Matsuda A, Kashiwakura I, Kuwabara M, Inanami O.

Br J Cancer. 2008 Nov 4;99(9):1442-52. doi: 10.1038/sj.bjc.6604720. Epub 2008 Oct 14.

8.

A Nucleoside Anticancer Drug, 1-(3-C-Ethynyl-β-D-Ribo-Pentofuranosyl)Cytosine, Induces Depth-Dependent Enhancement of Tumor Cell Death in Spread-Out Bragg Peak (SOBP) of Proton Beam.

Maeda K, Yasui H, Yamamori T, Matsuura T, Takao S, Suzuki M, Matsuda A, Inanami O, Shirato H.

PLoS One. 2016 Nov 22;11(11):e0166848. doi: 10.1371/journal.pone.0166848. eCollection 2016.

9.

BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks.

Wu L, Shao L, Li M, Zheng J, Wang J, Feng W, Chang J, Wang Y, Hauer-Jensen M, Zhou D.

Radiat Res. 2013 Feb;179(2):160-70. doi: 10.1667/RR3034.1. Epub 2012 Dec 21.

10.

A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.

Luo K, Li L, Li Y, Wu C, Yin Y, Chen Y, Deng M, Nowsheen S, Yuan J, Lou Z.

Genes Dev. 2016 Dec 1;30(23):2581-2595. doi: 10.1101/gad.289439.116. Epub 2016 Dec 9.

11.

Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil.

Takatori S, Kanda H, Takenaka K, Wataya Y, Matsuda A, Fukushima M, Shimamoto Y, Tanaka M, Sasaki T.

Cancer Chemother Pharmacol. 1999;44(2):97-104.

PMID:
10412942
12.

Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo.

Yu D, Sekine E, Fujimori A, Ochiya T, Okayasu R.

Cancer Sci. 2008 Apr;99(4):810-5. doi: 10.1111/j.1349-7006.2008.00741.x.

13.

Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51.

Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, Gong Y, Shao C.

PLoS One. 2011;6(8):e23427. doi: 10.1371/journal.pone.0023427. Epub 2011 Aug 8.

14.

An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.

Lui VW, Lau CP, Cheung CS, Ho K, Ng MH, Cheng SH, Hong B, Tsao SW, Tsang CM, Lei KI, Yamasaki Y, Mita A, Chan AT.

Biochem Pharmacol. 2010 Jun 15;79(12):1772-80. doi: 10.1016/j.bcp.2010.02.012. Epub 2010 Feb 26.

PMID:
20219441
15.

Impact of homologous recombination on individual cellular radiosensitivity.

Koch K, Wrona A, Dikomey E, Borgmann K.

Radiother Oncol. 2009 Feb;90(2):265-72. doi: 10.1016/j.radonc.2008.07.028. Epub 2008 Sep 17.

PMID:
18804300
16.

Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate.

Nikolova T, Ensminger M, Löbrich M, Kaina B.

DNA Repair (Amst). 2010 Oct 5;9(10):1050-63. doi: 10.1016/j.dnarep.2010.07.005. Epub 2010 Aug 13.

PMID:
20708982
17.

Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis.

Kasten-Pisula U, Windhorst S, Dahm-Daphi J, Mayr G, Dikomey E.

Radiother Oncol. 2007 Jun;83(3):296-303. Epub 2007 May 22.

PMID:
17521756
18.

Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.

Quiros S, Roos WP, Kaina B.

PLoS One. 2011;6(11):e27183. doi: 10.1371/journal.pone.0027183. Epub 2011 Nov 2.

19.

Therapeutic exploitation of tumor cell defects in homologous recombination.

Powell SN, Kachnic LA.

Anticancer Agents Med Chem. 2008 May;8(4):448-60. Review.

PMID:
18473729
20.

Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside-Nucleoside Analogue Radiosensitization.

Magin S, Papaioannou M, Saha J, Staudt C, Iliakis G.

Mol Cancer Ther. 2015 Jun;14(6):1424-33. doi: 10.1158/1535-7163.MCT-14-0682. Epub 2015 Apr 3.

Supplemental Content

Support Center